CJC-1295 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-09. Numbers and descriptions here follow the published literature rather than marketing material.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Assessed by visual inspection under ordinary light |
| Primary analytical method | Reversed-phase liquid chromatography | Purity estimated from peak area at 214 nm |
| Confirmatory method | Mass spectrometry | Observed mass compared with calculated value |
| Powder storage temperature | Minus 20 degrees Celsius | Minus 80 for extended archival periods |
| Solution stability | Hours to days at 2 to 8 degrees Celsius | Influenced by pH, buffer, and concentration |
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
This is a list of investigational Parkinson's disease drugs, or drugs that are currently under development for clinical use in the treatment of Parkinson's disease but are not yet approved. They may also be referred to as investigational antiparkinsonian agents. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]". This list was last comprehensively updated in September 2025. It is likely to become outdated with time.
== Structure and reactivity == DBNPA is a halogenated cyanoacetamide compound, characterized by the presence of two bromine atoms at the 2,2-position of the carbon backbone. DBNPA contains a cyano (-CN) group and an amide (-CONH2) group attached to a three-carbon chain. The molecular formula is C3H2Br2N2O, with a molecular weight of 241.87 g/mol. DBNPA is highly reactive due to the two electron-withdrawing bromine atoms and a cyano (-CN) group attached to the central carbon backbone. These substituents form a very electron-deficient core, making it highly vulnerable to nucleophilic attacks. The cyano group increases the reactivity of the compound by stabilizing the electron deficiency while the amide (−CONH2) group affects its water solubility. The electron-deficient carbon adjacent to the bromine atoms plays a critical role in DBNPA’s biocidal properties, leading to the disruption of microbial cellular functions. Since DBNPA is a highly reactive molecule, it is prone to pH-dependent hydrolysis at neutral and alkaline conditions because of the weak carbon-bromide bonds. DBNPA is also susceptible to be broken down in reducing environments by stepwise debromination. Additionally, DBNPA is highly sensitive to ultraviolet (UV) exposure, which accelerates its degradation in aqueous environments. Due to its reactive nature, DBNPA must be stabilized in products to prevent premature degradation before application.
At other times - for example, speaking at 2nd annual Memorial for Daniel Pearl, and in print in an article for The Atlantic - he had made comments against the terrorism against Jews in the Middle East. Hitchens stated "But the Jews of the Arab lands were expelled again in revenge for the defeat of Palestinian nationalistic aspirations, in 1947–48, and now the absolute most evil and discredited fabrication of Jew-baiting Christian Europe – The Protocols of the Elders of Zion – is eagerly promulgated in the Hamas charter and on the group's Web site and recycled through a whole nexus of outlets that includes schools as well as state-run television stations". In Slate magazine, Hitchens pondered the notion that, instead of curing antisemitism through the creation of a Jewish state, "Zionism has only replaced and repositioned" it, saying: "there are three groups of 6 million Jews. The first 6 million live in what the Zionist movement used to call Palestine. The second 6 million live in the United States. The third 6 million are distributed mainly among Russia, France, Britain, and Argentina. Only the first group lives daily in range of missiles that can be (and are) launched by people who hate Jews." Hitchens argued that instead of supporting Zionism, Jews should help "secularise and reform their own societies", believing that unless one is religious, "what the hell are you doing in the greater Jerusalem area in the first place?" Hitchens said that the only justification for Zionism given by Jews is a religious one.
– indicates that no information is available As a result of heparin's effect on such a wide variety of disease states, a number of drugs are indeed in development whose molecular structures are identical or similar to those found within parts of the polymeric heparin chain.
Sources: en.wikipedia.org
Donepezil: Donepezil is a widely used acetylcholinesterase inhibitor indicated for Alzheimer's disease. The drug can be administered orally or with a transdermal patch. However, the estimated time to peak will differ between both routes of administration. Oral donepezil has a peak concentration time of 3 to 8 hours depending on the dosage, while transdermal donepezil has an expected time to peak at 7 days.
=== June === June 1 A firefighter is killed and another injured in a shooting at a Los Angeles County Fire Department station in Santa Clarita. A special election is held in New Mexico to fill a vacancy in its 1st congressional district left by Deb Haaland when she resigned to become President Biden's Secretary of the Interior. Democrat Melanie Stansbury wins with 79,837 of the 132,262 votes cast (60.36%). COVID-19 pandemic SARS-CoV-2 Delta variant becomes the dominant strain of COVID-19 in the United States. COVID-19 vaccines – Moderna seeks full approval from the FDA for the Moderna COVID-19 vaccine. Michigan lifts several face mask requirements at outdoor gatherings and loosens them at indoor gatherings and businesses. Fully vaccinated people are allowed to not wear masks in public, but unvaccinated and partially vaccinated people are still required to do so. June 2 – Paul Allard Hodgkins, a Tampa man who was seen in the U.S. Senate chamber during the January 6 riot at the United States Capitol, pleads guilty, making him the second suspect to do so after Jon Schaffer. June 3 – The FBI announces that it has opened an investigation into Postmaster General Louis DeJoy over campaign fundraising. June 4 Facebook's Oversight Board announces its ban on former President Donald Trump's personal account will last until January 2023. Trump was originally banned for posting a message supporting the January 6 insurrectionists.
Aqueous normal-phase chromatography (ANP) is also called hydrophilic interaction liquid chromatography (HILIC). This is a chromatographic technique which encompasses the mobile phase region between reversed-phase chromatography (RP) and organic normal phase chromatography (ONP). HILIC is used to achieve unique selectivity for hydrophilic compounds, showing normal phase elution order, using "reversed-phase solvents", i.e., relatively polar mostly non-aqueous solvents in the mobile phase. Many biological molecules, especially those found in biological fluids, are small polar compounds that do not retain well by reversed phase-HPLC. This has made hydrophilic interaction LC (HILIC) an attractive alternative and useful approach for analysis of polar molecules. Additionally, because HILIC is routinely used with traditional aqueous mixtures with polar organic solvents such as ACN and methanol, it can be easily coupled to MS.
Sources: en.wikipedia.org
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.
Dry powder is markedly more stable than solution and is usually held frozen and desiccated. Room temperature exposure over days degrades it more slowly than most people assume, but long-term integrity favors freezer storage. Light protection is recommended regardless of temperature.
Methods, columns, gradients, and detection wavelengths are not standardized across laboratories. Some figures describe only the main peak area at one wavelength and ignore water, salts, or counter-ions. Without stated conditions, comparing reported percentages across sources is unreliable.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.